The digital transformation has led to significant advancements in authentication and identity verification technologies and other cyber defenses. From biometrics to multi-factor authentication (MFA) to use of Artificial Intelligence (AI) enhanced detection and response tools, these systems are the first line of critical defense against unauthorized access in critical sectors such as finance, healthcare, manufacturing and government. However, with the rapid development of Multi-Modal AI and agentic AI, a new challenge has emerged—one that may compromise the very systems designed to protect us. By integrating multiple forms of data (e.g., voice, video, text) in multi-modal AI and use of agentic AI (automated decision-making with little or no human intervention), malicious actors are increasingly capable of bypassing authentication and identity verification security and other defenses, thereby posing a new level of cybersecurity threat. The rapid deployment of AI integrated into a wide variety of commercial products, platforms and workflows has dramatically expanded the potential attack surface.
On July 26, 2023, the Securities and Exchange Commission (“SEC”) adopted its long-anticipated cybersecurity reporting rule (the “Final Rule”). The Final Rule applies to public companies subject to the reporting requirements of the Securities Exchange Act of 1934 and, in some cases, to foreign private issuers. As quoted in the SEC’s press release, SEC Commissioner Gary Gensler noted that many public companies already make cybersecurity disclosures to investors, and the Final Rule provides uniformity and structure for these future disclosures. The Final Rule also imposes a tight timeline for cybersecurity incident reporting and may include disclosure of an ongoing cybersecurity incident, as well as requiring periodic disclosures concerning organizational cybersecurity risk management processes and governance.
Blog Editors
Recent Updates
- DOGE's Attempt to Crowdsource Medicaid Fraud Scrutiny: Is This the Future of Healthcare Fraud Investigations?
- Feds vs. the States: Dr. Mehmet Oz Announces an Investigation Into New York’s Medicaid Program
- U.S. Supreme Court to Weigh Induced Infringement Case Regarding ‘Generic Version of Vascepa®’
- Closer Look at H.R. 7291: What the “GRAS Oversight and Transparency Act” Could Mean for Dietary Supplements
- Diagnostic Imaging Interoperability Request for Information Shines a Spotlight on the Lack of Patient-Centered Longitudinal Health Records